Twist Bioscience Corp. (TWST)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$124.72-3.10%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TWST
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 33.6% |
| Our one-year growth estimate | diamond | 24.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 9.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
TWST — earnings miss
Dated 2026-08-03
Results of Operations and Financial Condition. On August 3, 2026, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Se…
Why it matters: Strong revenue growth supports the raised guidance and shows business momentum.
Supportive ifQ3 FY26 revenue reported at $110M or higher.
Worry ifQ3 FY26 revenue falls below $100M, indicating weak performance.
Why it matters: Growing the customer base helps increase revenue and market presence. It shows the company’s sales strategy is working.
Supportive ifCustomer count exceeds 2,650 in Q4 FY26.
Worry ifCustomer count remains below 2,650 in Q4 FY26.
Why it matters: Exceeding this revenue target would confirm strong demand and growth momentum. It reflects the company's ability to expand its market.
Supportive ifTotal revenue for Q4 FY26 is above $123 million.
Worry ifTotal revenue for Q4 FY26 is below $123 million.
Why it matters: Achieving breakeven is key for future growth and investor confidence. It shows the company can manage costs better.
Supportive ifAdjusted EBITDA for Q4 FY26 is breakeven or better.
Worry ifAdjusted EBITDA is still negative for Q4 FY26.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$306 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $675 loss on $10,000 · 6.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,554 loss on $10,000 · 25.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Finishing this offering will give needed money for growth plans. It shows market trust in the company.
Watch forThe stock offering is done and the money is secured.
Also watch forThe stock offering is canceled or greatly reduced.
Why it matters: If health care revenue growth speeds up, it may help Twist Bioscience. This could improve investor sentiment.
Supportive ifHealth care revenue growth is speeding up again. It may reach 10% or more.
Worry ifHealth care revenue growth continues to slow below 10%.
Why it matters: Keeping this margin shows the company can manage costs while increasing revenue. It shows efficiency.
Supportive ifGross margin for Q4 FY26 is above 52%.
Worry ifGross margin for Q4 FY26 drops below 52%.